“Atopic Dermatitis – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Atopic Dermatitis Understanding
Atopic Dermatitis: Overview Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children. The primary symptom of AD is dry, itchy skin that often turns into a red rash. During a flare, AD becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-up. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from the presence of too many inflammatory cells in the skin. There is also evidence that people with AD have a compromised skin barrier compared to normal skin. Currently, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis. Currently, there is no cure for AD; however, it can be effectively managed with current treatment options.
"Atopic Dermatitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Dermatitis pipeline landscape is provided which includes the disease overview and Atopic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Dermatitis.
Atopic Dermatitis Emerging Drugs Chapters This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Atopic Dermatitis Emerging Drugs • Abrocitinib: Pfizer
Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). The drug received breakthrough therapy designation from the FDA to treat patients with moderate-to-severe AD in February 2018. In October 2020, based on the results of a robust Phase III clinical trial program, the FDA, accepted the filing of the company’s NDA for abrocitinib (100 mg and 200 mg) and granted priority review designation; the decision is anticipated April 2021. EMA accepted the MAA for the drug in the same patient population with a decision anticipated in the second half of 2021.
• Upadacitinib: AbbVie
Upadacitinib (ABT-494) was discovered and developed by AbbVie. It is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. The drug is currently under clinical developmental studies for atopic dermatitis, and several other immune-mediated diseases. • In October 2020, AbbVie submitted an application to the FDA and EMA seeking approval for Rinvoq for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate-to-severe AD. The atopic dermatitis indication applications to the FDA and EMA are supported by data from three pivotal Phase 3 studies.
• Tradipitant: Vanda Pharmaceuticals
Tradipitant is a small molecule based neurokinin 1 (NK1) receptor antagonist. Tradipitant is currently in phase III clinical development for gastroparesis, COVID-19 pneumonia, motion sickness and atopic dermatitis. Tradipitant licensed by Vanda from Eli Lilly and Company (Lilly) in April 2012. The patent describing tradipitant as a new chemical entity expires worldwide in April 2023, except in the United States, where it expires in June 2024.
• Nemolizumab: Galderma
Nemolizumab (CD14152) is a subcutaneously administered monoclonal antibody that antagonizes IL-31RA, a cytokine that plays a key role in the pathogenesis of moderate-to-severe AD, thereby blocking IL-31 signaling on its effector cells, including peripheral neurons. The drug was initially developed by Chugai Pharmaceutical and subsequently licensed to Galderma in 2016. Currently, the drug is being studied in Phase III trial as a once-daily oral therapy for moderate-to-severe AD in adults and in several other immune-mediated diseases.
• Lebrikizumab: Eli Lilly and Company
Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13R?1/IL-4R? heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The drug is being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.
• IDP 124: Ortho Dermatologics
Bausch Health Americas in collaboration with Ortho Dermatologics is developing IDP 124 for the treatment of patients with Atopic dermatitis. The drug is currently in phase 3 of clinical trials.
• SHR0302: Reistone Biopharma
SHR0302 is a highly selective small molecule based JAK 1 inhibitor. Reistone licensed in the drug from Jiangsu Hengrui Medicine and owns the global rights for multiple indications of autoimmune diseases. Reistone Biopharma is developing SHR0302 in linical studies with both oral and topical dosage forms for several immune-inflammatory diseases including Ulcerative Colitis, Crohn’s disease, etc. The high selectivity of SHR0302 may potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitors.
• MEDI3506: AstraZeneca
MEDI 3506 is an IL-33 (interleukin-33) monoclonal antibody being developed by AstraZeneca for the treatment of Atopic Dermatitis and chronic diabetic kidney disease. The drug is currently being studied in phase II stage of development for the treatment of patients with Atopic Dermatitis.
Further product details are provided in the report……..
Atopic Dermatitis: Therapeutic Assessment This segment of the report provides insights about the different Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Atopic Dermatitis
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Lysogene.
This report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Atopic Dermatitis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Dermatitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Dermatitis drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Atopic Dermatitis drugs?
• How many Atopic Dermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Dermatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atopic Dermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?
Our reports have been used by over 10K customers, including:
Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They also provide required nutrients to the patients suffering from diabetes, cancer and other diseases. Intravenous solutions...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
646 pages •
By Global Industry Analysts
• May 2021
Global Laparoscopic Devices Market to Reach $15.8 Billion by 2026
Laparoscopy is a form of minimally invasive surgery used in studying organs in pelvic and abdominal area of the body. The introduction of laparoscopic techniques revolutionized the surgical world through a gradual...
278 pages •
By Global Industry Analysts
• Apr 2021
- Global Anatomic Pathology Market to Reach $26.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anatomic Pathology estimated at US$18.7 Billion in the year 2020, is projected to reach a revised size of US$26.3 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027....
185 pages •
By Global Industry Analysts
• Apr 2021
- Global Pathology Instruments Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pathology Instruments estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027....
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Pathology Instruments Market 2021-2025 The analyst has been monitoring the pathology instruments market and it is poised to grow by $ 1.23 bn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on pathology instruments market provides a holistic analysis, market size and forecast,...
200 pages •
By The Business Research Company
• Mar 2021
Major players in the ultra-low temperature freezers market are Arctiko, Eppendorf, Esco Micro Pte Ltd, Haier, Helmer Scientific, Bionics Scientific Technologies (P). Ltd, PHC Holdings Corporation, Labcold Ltd, Remi Group, and Stirling Ultracold. The global ultra-low temperature freezers market is expected to decline from $633.94 million...
Anatomic Pathology Market Report Overview Anatomic Pathology market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anatomic Pathology market types and applications. It is a focused study on Anatomic Pathology market space including global...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.